It’s the most common childhood cancer we see, and cure rates are already high, but the treatment of ALL may be about to undergo a major shift. The next generation of Children’s Oncology Group (COG) trials in ALL, opening this summer, will determine whether new immunotherapies should be incorporated into first-line treatment. This presentation will provide an overview of these trials, the immunotherapies involved, and other changes in the standard backbone that will impact satellite healthcare providers.
Sumit Gupta, MD, PhD,
Staff Oncologist and Clinician Investigator,
The Hospital for Sick Children
Dr. Gupta is a Clinician Investigator and Staff Oncologist at The Hospital for Sick Children. His research concentrates on using clinical and health services data to identify and improve outcomes for vulnerable subgroups of children with cancer. He is also the co-chair of the next Children’s Oncology Group study for Standard Risk Acute Lymphoblastic Leukemia, AALL1731.